CVC Is Said to Explore Divestments for Recordati After Takeover

CVC Capital Partners Plc plans to explore options including potential divestments for Recordati SpA if it succeeds in its €10.9 billion ($12.5 billion) takeover of the Italian drugmaker, according to people familiar with the matter.

The investment firm could consider a sale of Recordati’s rare-diseases arm as one of the alternatives, the people said, asking not to be identified as the information is private. CVC may also look at selling other assets of the drugmaker, the people said.